Granules India Q2 net profit surges 39 pc to Rs 182 crore
Hyderabad, Nov 2 (TNT): Hyderabad-based pharmaceutical company Granules India Ltd on Monday reported a 39 per cent year-on-year increase in consolidated net profit at Rs 181.8 crore for the second quarter ended September 30, 2026, against Rs 130.6 crore in the corresponding period last fiscal.
The company’s revenue from operations grew 20 per cent to Rs 1,560 crore during the quarter, compared to Rs 1,297 crore in Q2 FY26.
EBITDA increased 21 per cent to Rs 337.6 crore from Rs 278.2 crore, while profit before tax (PBT) rose 38 per cent to Rs 243.4 crore against Rs 175.9 crore in the year-ago period, the Hyderabad company said in a release.
EBITDA margin improved to 22 per cent from 21 per cent.
Finished dosages contributed 73 per cent of the company’s revenue, followed by Active Pharmaceutical Ingredients (APIs) at 13 per cent, Pharmaceutical Formulation Intermediates (PFIs) at 10 per cent and Peptides CDMO at three per cent.
North America accounted for 72 per cent of the revenue, while Europe’s share stood at 16 per cent during the quarter.
The company ended the quarter with a net cash position of Rs 828 crore, compared to net debt of Rs 101.2 crore at the end of the previous quarter.
Commenting on the results, Granules India Chairman and Managing Director Dr Krishna Prasad Chigurupati said quarterly revenue crossed Rs 1,500 crore, with EBITDA of Rs 338 crore, despite higher input and logistics costs due to tensions in West Asia.
He said the company filed two potential first-to-file Abbreviated New Drug Applications (ANDAs) in the first half of FY27, taking the total to three, and would continue to focus on complex generics and peptide CDMO.
The company recently concluded a US FDA inspection at its Gagillapur facility. The inspection progressed constructively, and the observations could be addressed through responses and corrective and preventive actions, he added.
TNT TS
